{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:49:56Z","timestamp":1770223796280,"version":"3.49.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10741-017-9648-x","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T01:04:28Z","timestamp":1504141468000},"page":"879-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"22","author":[{"given":"Daniel J.","family":"Philipson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene C.","family":"DePasquale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold S.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"9648_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Circulation 92:785\u2013789. \nhttps:\/\/doi.org\/10.1161\/01.CIR.92.4.785","journal-title":"Circulation"},{"key":"9648_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","volume":"102","author":"BJ Maron","year":"2000","unstructured":"Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102:858\u2013864. \nhttps:\/\/doi.org\/10.1161\/01.CIR.102.8.858","journal-title":"Circulation"},{"key":"9648_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","volume":"42","author":"BJ Maron","year":"2003","unstructured":"Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology\/European Society of Cardiology Clinical Expert Consensus Document on hypertrophic cardiomyopathy. J Am Coll Cardiol 42:1687\u20131713. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(03)00941-0","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrcardio.2016.140","volume":"13","author":"S Sen-Chowdhry","year":"2016","unstructured":"Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ (2016) Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol 13:651\u2013675. \nhttps:\/\/doi.org\/10.1038\/nrcardio.2016.140","journal-title":"Nat Rev Cardiol"},{"key":"9648_CR5","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG et al (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232\u20132239. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.644682","journal-title":"Circulation"},{"key":"9648_CR6","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","volume":"33","author":"R Spoladore","year":"2012","unstructured":"Spoladore R, Maron MS, D\u2019Amato R et al (2012) Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 33:1724\u20131733. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehs150","journal-title":"Eur Heart J"},{"key":"9648_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"E Ammirati","year":"2016","unstructured":"Ammirati E, Contri R, Coppini R et al (2016) Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 18:1106\u20131118. \nhttps:\/\/doi.org\/10.1002\/ejhf.541","journal-title":"Eur J Heart Fail"},{"key":"9648_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","volume":"55","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Tuzcu EM, Desai MY et al (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55:823\u2013834. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2009.09.047","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jacc.2006.08.055","volume":"49","author":"US Valeti","year":"2007","unstructured":"Valeti US, Nishimura RA, Holmes DR et al (2007) Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:350\u2013357. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2006.08.055","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","volume":"3","author":"M Liebregts","year":"2015","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK et al (2015) A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Hear Fail 3:896\u2013905. \nhttps:\/\/doi.org\/10.1016\/j.jchf.2015.06.011","journal-title":"JACC Hear Fail"},{"key":"9648_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1172\/JCI200214677","volume":"109","author":"C Semsarian","year":"2002","unstructured":"Semsarian C, Ahmad I, Giewat M et al (2002) The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 109:1013\u20131020. \nhttps:\/\/doi.org\/10.1172\/JCI200214677","journal-title":"J Clin Invest"},{"key":"9648_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","volume":"3","author":"CY Ho","year":"2015","unstructured":"Ho CY, Lakdawala NK, Cirino AL et al (2015) Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Hear Fail 3:180\u2013188. \nhttps:\/\/doi.org\/10.1016\/j.jchf.2014.08.003","journal-title":"JACC Hear Fail"},{"key":"9648_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini R, Ferrantini C, Yao L et al (2013) Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127:575\u2013584. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.134932","journal-title":"Circulation"},{"key":"9648_CR14","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","volume":"68","author":"JL Gentry","year":"2016","unstructured":"Gentry JL, Mentz RJ, Hurdle M, Wang A (2016) Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol 68:1815\u20131817. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2016.07.758","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR15","unstructured":"Bemporad D (2016) Ranolazine in patients with symptomatic hypertrophic cardiomyopathy: a pilot study assessing the effects on exercise capacity, diastolic function and symptomatic status. EU Clin Trials Regist. \nhttps:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-004507-20\/DE\n\n. Accessed August 1, 2016"},{"key":"9648_CR16","unstructured":"Gilead Sciences (2017) Effect of eleclazine (GS-6615) on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM). US National Library of Medicine. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02291237\n\n. Accessed February 17, 2017"},{"key":"9648_CR17","unstructured":"Gilead Sciences (2017) Effect of eleclazine on shortening of the QT interval, safety, and tolerability in adults with long QT syndrome type 3. US National Library of Medicine. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02300558?te\n\n. Accessed February 17, 2017"},{"key":"9648_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.1500511","volume":"1","author":"S Nag","year":"2015","unstructured":"Nag S, Sommese RF, Ujfalusi Z et al (2015) Contractility parameters of human beta-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. Sci Adv 1:1\u201316. \nhttps:\/\/doi.org\/10.1126\/sciadv.1500511","journal-title":"Sci Adv"},{"key":"9648_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cardfail.2015.04.010","volume":"21","author":"F Kamdar","year":"2015","unstructured":"Kamdar F, Klaassen Kamdar A, Koyano-Nakagawa N et al (2015) Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies. J Card Fail 21:761\u2013770. \nhttps:\/\/doi.org\/10.1016\/j.cardfail.2015.04.010","journal-title":"J Card Fail"},{"key":"9648_CR20","doi-asserted-by":"publisher","first-page":"H387","DOI":"10.1152\/ajpheart.00737.2006","volume":"292","author":"MY Maslov","year":"2007","unstructured":"Maslov MY, Chacko VP, Stuber M et al (2007) Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 292:H387\u2013H391. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00737.2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9648_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12265-009-9131-8","volume":"2","author":"C Ferrantini","year":"2009","unstructured":"Ferrantini C, Belus A, Piroddi N et al (2009) Mechanical and energetic consequences of HCM-causing mutations. J Cardiovasc Transl Res 2:441\u2013451. \nhttps:\/\/doi.org\/10.1007\/s12265-009-9131-8","journal-title":"J Cardiovasc Transl Res"},{"key":"9648_CR22","doi-asserted-by":"publisher","unstructured":"Wilder T, Ryba DM, Wieczorek DF et al (2015) N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. doi:\nhttps:\/\/doi.org\/10.1152\/ajpheart.00339.2015","DOI":"10.1152\/ajpheart.00339.2015"},{"key":"9648_CR23","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","volume":"112","author":"L Lee","year":"2005","unstructured":"Lee L, Campbell R, Scheuermann-Freestone M et al (2005) Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112:3280\u20133288. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.551457","journal-title":"Circulation"},{"key":"9648_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0167-5273(86)90146-4","volume":"13","author":"JD Horowitz","year":"1986","unstructured":"Horowitz JD, Sia STB, Macdonald PS et al (1986) Perhexiline maleate treatment for severe angina pectoris\u2014correlations with pharmacokinetics. Int J Cardiol 13:219\u2013229. \nhttps:\/\/doi.org\/10.1016\/0167-5273(86)90146-4","journal-title":"Int J Cardiol"},{"key":"9648_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0735-1097(02)02713-4","volume":"41","author":"I Olivotto","year":"2003","unstructured":"Olivotto I, Gistri R, Petrone P et al (2003) Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 41:315\u2013321. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(02)02713-4","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","volume":"1","author":"YJ Shimada","year":"2013","unstructured":"Shimada YJ, Passeri JJ, Baggish AL et al (2013) Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Hear Fail 1:480\u2013487. \nhttps:\/\/doi.org\/10.1016\/j.jchf.2013.09.001","journal-title":"JACC Hear Fail"},{"key":"9648_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","volume":"3","author":"A Axelsson","year":"2015","unstructured":"Axelsson A, Iversen K, Vejlstrup N et al (2015) Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 3:123\u2013131. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(14)70241-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9648_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jacc.2013.10.021","volume":"64","author":"DS Lim","year":"2014","unstructured":"Lim DS, Reynolds MR, Feldman T et al (2014) Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 64:182\u2013192. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.10.021","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.jacc.2004.04.063","volume":"44","author":"BJ Maron","year":"2004","unstructured":"Maron BJ, Dearani JA, Ommen SR et al (2004) The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2044\u20132053. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2004.04.063","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00392-004-0097-x","volume":"93","author":"T Lawrenz","year":"2004","unstructured":"Lawrenz T, Kuhn HJ (2004) Endocardial radiofrequency ablation of septal hypertrophy: a new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol 93:493\u2013499","journal-title":"Z Kardiol"},{"key":"9648_CR31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/CIRCRESAHA.107.158774","volume":"101","author":"L Pohlmann","year":"2007","unstructured":"Pohlmann L, Kr\u00f6ger I, Vignier N et al (2007) Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res 101:928\u2013938. \nhttps:\/\/doi.org\/10.1161\/CIRCRESAHA.107.158774","journal-title":"Circ Res"},{"key":"9648_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/cvr\/cvm113","volume":"77","author":"B Iorga","year":"2008","unstructured":"Iorga B, Blaudeck N, Solzin J et al (2008) Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils. Cardiovasc Res 77:676\u2013686. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvm113","journal-title":"Cardiovasc Res"},{"key":"9648_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.yjmcc.2010.01.011","volume":"48","author":"S Huke","year":"2010","unstructured":"Huke S, Knollmann BC (2010) Increased myofilament Ca2+ sensitivity and arrhythmia susceptibility. J Mol Cell Cardiol 48:824\u2013833. \nhttps:\/\/doi.org\/10.1016\/j.yjmcc.2010.01.011","journal-title":"J Mol Cell Cardiol"},{"key":"9648_CR34","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1172\/JCI36642","volume":"118","author":"F Baudenbacher","year":"2008","unstructured":"Baudenbacher F, Schober T, Pinto JR et al (2008) Myofilament Ca sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 118:3845\u20133903. \nhttps:\/\/doi.org\/10.1172\/JCI36642","journal-title":"J Clin Invest"},{"key":"9648_CR35","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","volume":"105","author":"CY Ho","year":"2002","unstructured":"Ho CY, Sweitzer NK, McDonough B et al (2002) Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105:2992\u20132997. \nhttps:\/\/doi.org\/10.1161\/01.CIR.0000019070.70491.6D","journal-title":"Circulation"},{"key":"9648_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/01.CIR.104.2.128","volume":"104","author":"SF Nagueh","year":"2001","unstructured":"Nagueh SF, Bachinski LL, Meyer D et al (2001) Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104:128\u2013130. \nhttps:\/\/doi.org\/10.1161\/01.CIR.104.2.128","journal-title":"Circulation"},{"key":"9648_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/70990","volume":"5","author":"D Michele","year":"1999","unstructured":"Michele D, Albayya FP, Metzger JM (1999) Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes. Nat Med 5:1413\u20131417. \nhttps:\/\/doi.org\/10.1038\/70990","journal-title":"Nat Med"},{"key":"9648_CR38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/81321","volume":"6","author":"N Frey","year":"2000","unstructured":"Frey N, McKinsey TA, Olson EN (2000) Decoding calcium signals involved in cardiac growth and function. Nat Med 6:1221\u20131227. \nhttps:\/\/doi.org\/10.1038\/81321","journal-title":"Nat Med"},{"key":"9648_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cvr\/cvv023","volume":"105","author":"JC Tardiff","year":"2015","unstructured":"Tardiff JC, Carrier L, Bers DM et al (2015) Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res 105:457\u2013470. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvv023","journal-title":"Cardiovasc Res"},{"key":"9648_CR40","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/CIRCRESAHA.107.156380","volume":"101","author":"P Robinson","year":"2007","unstructured":"Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 101:1266\u20131273. \nhttps:\/\/doi.org\/10.1161\/CIRCRESAHA.107.156380","journal-title":"Circ Res"},{"key":"9648_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI11093","volume":"106","author":"D Fatkin","year":"2000","unstructured":"Fatkin D, Mcconnell BK, Mudd JO et al (2000) An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 106:1351\u20131359. \nhttps:\/\/doi.org\/10.1172\/JCI11093","journal-title":"J Clin Invest"},{"key":"9648_CR42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/CIRCRESAHA.111.258251","volume":"110","author":"JD Lovelock","year":"2012","unstructured":"Lovelock JD, Monasky MM, Jeong EM et al (2012) Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110:841\u2013850. \nhttps:\/\/doi.org\/10.1161\/CIRCRESAHA.111.258251","journal-title":"Circ Res"},{"key":"9648_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/cvr\/cvv247","volume":"109","author":"F Flenner","year":"2016","unstructured":"Flenner F, Friedrich FW, Ungeheuer N et al (2016) Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovasc Res 109:90\u2013102. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvv247","journal-title":"Cardiovasc Res"},{"key":"9648_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tcm.2008.04.001","volume":"18","author":"M Buvoli","year":"2008","unstructured":"Buvoli M, Hamady M, Leinwand LA, Knight R (2008) Bioinformatics assessment of \u03b2-myosin mutations reveals myosin\u2019s high sensitivity to mutations. Trends Cardiovasc Med 18:141\u2013149. \nhttps:\/\/doi.org\/10.1016\/j.tcm.2008.04.001","journal-title":"Trends Cardiovasc Med"},{"key":"9648_CR45","doi-asserted-by":"publisher","first-page":"H1242","DOI":"10.1152\/ajpheart.00686.2004","volume":"288","author":"SE Kirschner","year":"2004","unstructured":"Kirschner SE, Becker E, Antognozzi M et al (2004) Hypertrophic cardiomyopathy-related-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. AJP Hear Circ Physiol 288:H1242\u2013H1251. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00686.2004","journal-title":"AJP Hear Circ Physiol"},{"key":"9648_CR46","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.bpj.2014.02.011","volume":"106","author":"JA Spudich","year":"2014","unstructured":"Spudich JA (2014) Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J 106:1236\u20131249. \nhttps:\/\/doi.org\/10.1016\/j.bpj.2014.02.011","journal-title":"Biophys J"},{"key":"9648_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000252808","volume":"115","author":"R Walsh","year":"2009","unstructured":"Walsh R, Rutland C, Thomas R, Loughna S (2009) Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. Cardiology 115:49\u201360. \nhttps:\/\/doi.org\/10.1159\/000252808","journal-title":"Cardiology"},{"issue":"80","key":"9648_CR48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(80):617\u2013621","journal-title":"Science"},{"key":"9648_CR49","unstructured":"MyoKardia Inc (2015) MyoKardia provides update on two phase 1 trials of MYK-461 for the treatment of hypertrophic cardiomyopathy. In: \nhttp:\/\/investors.myokardia.com\/phoenix.zhtml?c=254211&p=irol-newsArticle&ID=2097088"},{"key":"9648_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends ER, G\u00fccl\u00fc A, Germans T et al (2014) Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res 103:248\u2013257. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvu127","journal-title":"Cardiovasc Res"},{"key":"9648_CR51","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1113\/jphysiol.2014.274571","volume":"592","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends ER, Ferrara C, Scellini B et al (2014) Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation. J Physiol 592:3257\u20133272. \nhttps:\/\/doi.org\/10.1113\/jphysiol.2014.274571","journal-title":"J Physiol"},{"key":"9648_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","volume":"19","author":"H Ashrafian","year":"2003","unstructured":"Ashrafian H, Redwood C, Blair E, Watkins H (2003) Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19:263\u2013268. \nhttps:\/\/doi.org\/10.1016\/S0168-9525(03)00081-7","journal-title":"Trends Genet"},{"key":"9648_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","volume":"65","author":"N Frey","year":"2003","unstructured":"Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45\u201379. \nhttps:\/\/doi.org\/10.1146\/annurev.physiol.65.092101.142243","journal-title":"Annu Rev Physiol"},{"key":"9648_CR54","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/hmg\/10.11.1215","volume":"10","author":"E Blair","year":"2001","unstructured":"Blair E, Redwood C, Ashrafian H et al (2001) Mutations in the \u03b3 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10:1215\u20131220. \nhttps:\/\/doi.org\/10.1093\/hmg\/10.11.1215","journal-title":"Hum Mol Genet"},{"key":"9648_CR55","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley JG, Boehm EA, Blair E et al (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41:1776\u20131782. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(02)03009-7","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR56","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/eurheartj\/ehp184","volume":"30","author":"K Unno","year":"2009","unstructured":"Unno K, Isobe S, Izawa H et al (2009) Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J 30:1853\u20131862. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehp184","journal-title":"Eur Heart J"},{"key":"9648_CR57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0735-1097(91)90869-B","volume":"17","author":"P Camici","year":"1991","unstructured":"Camici P, Chiriatti G, Lorenzoni R et al (1991) Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 17:879\u2013886. \nhttps:\/\/doi.org\/10.1016\/0735-1097(91)90869-B","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR58","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","volume":"349","author":"F Cecchi","year":"2003","unstructured":"Cecchi F, Olivotto I, Gistri R et al (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349:1027\u20131035","journal-title":"N Engl J Med"},{"key":"9648_CR59","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","volume":"115","author":"SE Petersen","year":"2007","unstructured":"Petersen SE, Jerosch-Herold M, Hudsmith LE et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115:2418\u20132425. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.657023","journal-title":"Circulation"},{"key":"9648_CR60","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501.Resolution","volume":"119","author":"R Lombardi","year":"2009","unstructured":"Lombardi R, Rodriguez G, Chen SN et al (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398\u20131407. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.790501.Resolution","journal-title":"Circulation"},{"key":"9648_CR61","unstructured":"Marian AJ (2015) Hypertrophic regression with N-Acetylcysteine in HCM (HALT). US National Library of Medicine. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01537926?\n\n. Accessed February 17, 2017"},{"key":"9648_CR62","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/01.CIR.92.10.2886","volume":"92","author":"SS Lele","year":"1995","unstructured":"Lele SS, Thomson HL, Seo H et al (1995) Exercise capacity in hypertrophic cardiomyopathy. Circulation 92:2886\u20132894","journal-title":"Circulation"},{"key":"9648_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCHEARTFAILURE.109.877720","volume":"3","author":"TT Phan","year":"2010","unstructured":"Phan TT, Shivu GN, Abozguia K et al (2010) Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Hear Fail 3:29\u201334. \nhttps:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.877720","journal-title":"Circ Hear Fail"},{"key":"9648_CR64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00005344-199503000-00018","volume":"25","author":"FMH Jeffrey","year":"1995","unstructured":"Jeffrey FMH, Alvarez L, Diczku V et al (1995) Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 25:469\u2013472","journal-title":"J Cardiovasc Pharmacol"},{"key":"9648_CR65","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia K, Elliott P, McKenna W et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562\u20131569. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.934059","journal-title":"Circulation"},{"key":"9648_CR66","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/01.CIR.81.4.1260","volume":"81","author":"PL Cole","year":"1990","unstructured":"Cole PL, Beamer AD, Mcgowan N et al (1990) Efficacy and safet of perhexiline maleate refractory angina a double-blind placebo-controlled clinical trial of a novel. Circulation 81:1260\u20131270","journal-title":"Circulation"},{"key":"9648_CR67","unstructured":"Heart Metabolics Limited (2015) Efficacy, safety, and tolerability of perhexiline in subjects with hypertrophic cardiomyopathy and heart failure. US National Library of Medicine. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02431221\n\n. Accessed February 17, 2017"},{"key":"9648_CR68","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/heart.84.5.476","volume":"84","author":"AM Varnava","year":"2000","unstructured":"Varnava AM, Elliott PM, Sharma S et al (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84:476\u2013482. \nhttps:\/\/doi.org\/10.1136\/heart.84.5.476","journal-title":"Heart"},{"key":"9648_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(99)06187-5","volume":"355","author":"AJ Marian","year":"2000","unstructured":"Marian AJ (2000) Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355:58\u201360. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(99)06187-5","journal-title":"Lancet"},{"key":"9648_CR70","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1056\/NEJM198603273141302","volume":"320","author":"P Spirito","year":"1989","unstructured":"Spirito P, Chiarella F, Carratino L et al (1989) Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 320:749\u2013755. \nhttps:\/\/doi.org\/10.1056\/NEJM198603273141302","journal-title":"N Engl J Med"},{"key":"9648_CR71","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","volume":"357","author":"PM Elliott","year":"2001","unstructured":"Elliott PM, Gimeno Blanes JR, Mahon NG et al (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357:420\u2013424. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(00)04005-8","journal-title":"Lancet"},{"key":"9648_CR72","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0735-1097(03)00855-6","volume":"42","author":"BJ Maron","year":"2003","unstructured":"Maron BJ, Casey SA, Hauser RG, Aeppli DM (2003) Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 42:882\u2013888. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(03)00855-6","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR73","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028DS1","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul P, Eminaga S, Toka O et al (2010) Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-\u03b2. J Clin Invest 120:3520\u20133529. \nhttps:\/\/doi.org\/10.1172\/JCI42028DS1","journal-title":"J Clin Invest"},{"key":"9648_CR74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","volume":"103","author":"D Lim","year":"2001","unstructured":"Lim D, Lutucuta S, Bachireddy P et al (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789\u2013792","journal-title":"Circulation"},{"key":"9648_CR75","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1253\/circj.69.1244","volume":"69","author":"H Kawano","year":"2005","unstructured":"Kawano H, Toda G, Nakamizo R et al (2005) Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 69:1244\u20131248","journal-title":"Circ J"},{"key":"9648_CR76","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","volume":"96","author":"AQ Araujo","year":"2005","unstructured":"Araujo AQ, Arteaga E, Ianni BM et al (2005) Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 96:1563\u20131567. \nhttps:\/\/doi.org\/10.1016\/j.amjcard.2005.07.065","journal-title":"Am J Cardiol"},{"key":"9648_CR77","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1536\/ihj.48.715","volume":"48","author":"T Yamazaki","year":"2007","unstructured":"Yamazaki T, Suzuki J-I, Shimamoto R et al (2007) A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 48:715\u2013724. \nhttps:\/\/doi.org\/10.1536\/ihj.48.715","journal-title":"Int Heart J"},{"key":"9648_CR78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","volume":"11","author":"M Penicka","year":"2009","unstructured":"Penicka M, Gregor P, Kerekes R et al (2009) The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy. J Mol Diagnostics 11:35\u201341. \nhttps:\/\/doi.org\/10.2353\/jmoldx.2009.080082","journal-title":"J Mol Diagnostics"},{"key":"9648_CR79","unstructured":"US National Library of Medicine (2016) \nclinicaltrials.gov\n\n \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01912534"},{"key":"9648_CR80","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332\\r348\/4\/295","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295\u2013303. \nhttps:\/\/doi.org\/10.1056\/NEJMoa021332\\r348\/4\/295","journal-title":"N Engl J Med"},{"key":"9648_CR81","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/01.CIR.35.6.1100","volume":"36","author":"ED Wigle","year":"1967","unstructured":"Wigle ED, Marquis Y, Auger P (1967) Muscular subaortic stenosis: initial left ventricular inflow tract pressure in the assessment of intraventricular pressures differences in man. Circulation 36:1100\u20131117","journal-title":"Circulation"},{"key":"9648_CR82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.34.4.558","volume":"34","author":"J Ross","year":"1966","unstructured":"Ross J, Braunwald E, Gault JH et al (1966) The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation 34:558\u2013578","journal-title":"Circulation"},{"key":"9648_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/01.CIR.40.1.3","volume":"40","author":"PM Shah","year":"1969","unstructured":"Shah PM, Gramiak R, Kramer D (1969) Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation 40:3\u201311. \nhttps:\/\/doi.org\/10.1161\/01.CIR.40.1.3","journal-title":"Circulation"},{"key":"9648_CR84","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/0735-1097(89)90326-4","volume":"13","author":"EG Cape","year":"1989","unstructured":"Cape EG, Simons D, Jimoh A et al (1989) Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies. J Am Coll Cardiol 13:1438\u20131448. \nhttps:\/\/doi.org\/10.1016\/0735-1097(89)90326-4","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR85","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","volume":"67","author":"MV Sherrid","year":"2016","unstructured":"Sherrid MV, Balaram S, Kim B et al (2016) The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J Am Coll Cardiol 67:1846\u20131858. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2016.01.071","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR86","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0002-9149(84)80141-1","volume":"54","author":"P Spirito","year":"1984","unstructured":"Spirito P, Maron BJ (1984) Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. Am J Cardiol 54:1039\u20131046. \nhttps:\/\/doi.org\/10.1016\/S0002-9149(84)80141-1","journal-title":"Am J Cardiol"},{"key":"9648_CR87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0735-1097(92)90135-A","volume":"20","author":"LE Grigg","year":"1992","unstructured":"Grigg LE, Wigle ED, Williams WG et al (1992) Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 20:42\u201352. \nhttps:\/\/doi.org\/10.1016\/0735-1097(92)90135-A","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR88","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.98.9.856","volume":"98","author":"E Schwammenthal","year":"1998","unstructured":"Schwammenthal E, Nakatani S, He S et al (1998) Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 98:856\u2013865","journal-title":"Circulation"},{"key":"9648_CR89","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/S0735-1097(00)01019-6","volume":"36","author":"EHC Yu","year":"2000","unstructured":"Yu EHC, Omran AS, Wigle ED et al (2000) Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 36:2219\u20132225. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(00)01019-6","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","volume":"85","author":"NG Smedira","year":"2008","unstructured":"Smedira NG, Lytle BW, Lever HM et al (2008) Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 85:127\u2013133. \nhttps:\/\/doi.org\/10.1016\/j.athoracsur.2007.07.063","journal-title":"Ann Thorac Surg"},{"key":"9648_CR91","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.athoracsur.2008.07.048","volume":"86","author":"SK Balaram","year":"2008","unstructured":"Balaram SK, Tyrie L, Sherrid MV et al (2008) Resection-plication-release for hypertrophic cardiomyopathy: clinical and echocardiographic follow-up. Ann Thorac Surg 86:1539\u20131545. \nhttps:\/\/doi.org\/10.1016\/j.athoracsur.2008.07.048","journal-title":"Ann Thorac Surg"},{"key":"9648_CR92","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.athoracsur.2012.06.008","volume":"94","author":"SK Balaram","year":"2012","unstructured":"Balaram SK, Ross RE, Sherrid MV et al (2012) Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann Thorac Surg 94:1990\u20131998. \nhttps:\/\/doi.org\/10.1016\/j.athoracsur.2012.06.008","journal-title":"Ann Thorac Surg"},{"key":"9648_CR93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/jocs.12804","volume":"31","author":"AA Shah","year":"2016","unstructured":"Shah AA, Glower DD, Gaca JG (2016) Trans-aortic Alfieri stitch at the time of septal myectomy for hypertrophic obstructive cardiomyopathy. J Card Surg 31:503\u2013506. \nhttps:\/\/doi.org\/10.1111\/jocs.12804","journal-title":"J Card Surg"},{"key":"9648_CR94","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","volume":"66","author":"P Ferrazzi","year":"2015","unstructured":"Ferrazzi P, Spirito P, Iacovoni A et al (2015) Transaortic chordal cutting mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J Am Coll Cardiol 66:1687\u20131696. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2015.07.069","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR95","doi-asserted-by":"publisher","unstructured":"Maron BJ, Dearani JA, Maron MS, et al (2017) Why we need more septal myectomy surgeons: an emerging recognition. J Thorac Cardiovasc Surg 1\u20136. doi:\nhttps:\/\/doi.org\/10.1016\/j.jtcvs.2016.12.038","DOI":"10.1016\/j.jtcvs.2016.12.038"},{"key":"9648_CR96","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","volume":"364","author":"T Feldman","year":"2011","unstructured":"Feldman T, Foster E, Glower DD et al (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364:1395\u20131406","journal-title":"N Engl J Med"},{"key":"9648_CR97","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2013.04.030","volume":"62","author":"L Mauri","year":"2013","unstructured":"Mauri L, Foster E, Glower DD et al (2013) 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 62:317\u2013328. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.04.030","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR98","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/S0735-1097(16)31517-0","volume":"67","author":"P Sorajja","year":"2016","unstructured":"Sorajja P, Pedersen W, Bae R et al (2016) First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 67:1516. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(16)31517-0","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.echo.2007.01.015","volume":"20","author":"WA Jaber","year":"2007","unstructured":"Jaber WA, Nishimura RA, Ommen SR (2007) Not all systolic velocities indicate obstruction in hypertrophic cardiomyopathy: a simultaneous Doppler catheterization study. J Am Soc Echocardiogr 20:5\u20137. \nhttps:\/\/doi.org\/10.1016\/j.echo.2007.01.015","journal-title":"J Am Soc Echocardiogr"},{"key":"9648_CR100","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/pgmj.62.728.515","volume":"62","author":"JM Criley","year":"1986","unstructured":"Criley JM, Siegel RJ (1986) Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy. Postgrad Med J 62:515\u2013529. \nhttps:\/\/doi.org\/10.1136\/pgmj.62.728.515","journal-title":"Postgrad Med J"},{"key":"9648_CR101","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1172\/JCI109990","volume":"66","author":"JP Murgo","year":"1980","unstructured":"Murgo JP, Alter BR, Dorethy JF et al (1980) Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. J Clin Invest 66:1369\u20131382. \nhttps:\/\/doi.org\/10.1172\/JCI109990","journal-title":"J Clin Invest"},{"key":"9648_CR102","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0735-1097(96)00590-6","volume":"29","author":"JM Criley","year":"1997","unstructured":"Criley JM (1997) Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy. J Am Coll Cardiol 29:741\u2013743. \nhttps:\/\/doi.org\/10.1016\/S0735-1097(96)00590-6","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR103","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0735-1097(89)90615-3","volume":"13","author":"DJ Sahn","year":"1989","unstructured":"Sahn DJ, Yoganathan AP, Editors G et al (1989) Pressure recovery distal to a stenosis: potential cause of a gradient \u201coverestimation\u201d by Doppler echocardiography. J Am Coll Cardiol 13:706\u2013715","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR104","doi-asserted-by":"publisher","first-page":"IV-3","DOI":"10.1161\/01.CIR.29.5S4.IV-3","volume":"29","author":"E Braunwald","year":"1964","unstructured":"Braunwald E, Lambrew CT, Rockoff SD et al (1964) Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation 29:IV-3\u2013IV-119. \nhttps:\/\/doi.org\/10.1161\/01.CIR.29.5S4.IV-3","journal-title":"Circulation"},{"key":"9648_CR105","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/clc.20594","volume":"32","author":"JB Geske","year":"2009","unstructured":"Geske JB, Sorajja P, Ommen SR, Nishimura RA (2009) Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol 32:397\u2013402. \nhttps:\/\/doi.org\/10.1002\/clc.20594","journal-title":"Clin Cardiol"},{"key":"9648_CR106","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jcin.2011.02.014","volume":"4","author":"JB Geske","year":"2011","unstructured":"Geske JB, Sorajja P, Ommen SR, Nishimura RA (2011) Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv 4:704\u2013709. \nhttps:\/\/doi.org\/10.1016\/j.jcin.2011.02.014","journal-title":"JACC Cardiovasc Interv"},{"key":"9648_CR107","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","volume":"37","author":"J Veselka","year":"2016","unstructured":"Veselka J, Jensen MK, Liebregts M et al (2016) Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 37:1517\u20131523. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv693","journal-title":"Eur Heart J"},{"key":"9648_CR108","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","volume":"389","author":"J Veselka","year":"2017","unstructured":"Veselka J, Anavekar NS, Charron P (2017) Hypertrophic obstructive cardiomyopathy. Lancet 389:1253\u20131267. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)31321-6","journal-title":"Lancet"},{"key":"9648_CR109","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","volume":"57","author":"T Lawrenz","year":"2011","unstructured":"Lawrenz T, Borchert B, Leuner C et al (2011) Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6\u00a0months\u2019 follow-up in 19 patients. J Am Coll Cardiol 57:572\u2013576. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2010.07.055","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR110","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.jacc.2011.09.020","volume":"58","author":"N Sreeram","year":"2011","unstructured":"Sreeram N, Emmel M, De Giovanni JV (2011) Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol 58:2501\u20132510. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2011.09.020","journal-title":"J Am Coll Cardiol"},{"key":"9648_CR111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/europace\/euv302","volume":"18","author":"RM Cooper","year":"2015","unstructured":"Cooper RM, Shahzad A, Hasleton J et al (2015) Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound\u00ae technology to guide ablation. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol 18:113\u2013120. \nhttps:\/\/doi.org\/10.1093\/europace\/euv302","journal-title":"Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"9648_CR112","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.hrthm.2016.04.018","volume":"13","author":"K Crossen","year":"2016","unstructured":"Crossen K, Jones M, Erikson C (2016) Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Hear Rhythm 13:1885\u20131890. \nhttps:\/\/doi.org\/10.1016\/j.hrthm.2016.04.018","journal-title":"Hear Rhythm"},{"key":"9648_CR113","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ihj.2016.02.007","volume":"68","author":"AB Shelke","year":"2016","unstructured":"Shelke AB, Menon R, Kapadiya A et al (2016) A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Indian Heart J 68:618\u2013623. \nhttps:\/\/doi.org\/10.1016\/j.ihj.2016.02.007","journal-title":"Indian Heart J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-017-9648-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9648-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-017-9648-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T06:40:38Z","timestamp":1507617638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-017-9648-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["9648"],"URL":"https:\/\/doi.org\/10.1007\/s10741-017-9648-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}